Recombinant human basic fibroblast growth factor accelerates fracture healing by enhancing callus remodeling in experimental dog tibial fracture.
Effect of recombinant human basic fibroblast growth factor (bFGF) on fracture healing was investigated using a tibial fracture in beagle dogs. Transverse fractures in the middle of the diaphyses were created in the right tibiae and bFGF was injected into the fracture sites at a single dose of 200 micrograms. The time course of changes in callus volume and morphology of the fracture sites were evaluated at weeks 2, 4, 8, 16, and 32 after treatment, and the fracture strength was analyzed at weeks 16 and 32. At week 2, a radiogram of the fracture site showed obvious membranous ossification in the group injected with bFGF. Basic FGF extended the callus area at week 4 and increased the bone mineral content (BMC) in the callus at week 8. bFGF also increased the osteoclast number in the periosteal callus at weeks 2 and 4. In the bFGF group, a maximal increase in the osteoclast index was found at week 4, and an identical increase was recognized in the control group at weeks 8 and 16. These findings strongly suggested that bFGF stimulated not only callus formation but osteoclastic callus resorption. BMC in the bFGF group was followed by a rapid decrease from week 8, while that in the control group was identical from week 4. Fracture strength of the bFGF group showed significant recovery by week 16, and recovery was still evident by week 32. We conclude that bFGF promotes the fracture healing in dogs by the stimulation of bone remodeling.
Nakamura
T
T
Department of Surgery, Nippon Veterinary and Animal Science University, Tokyo, Japan.
Hara
Y
Y
Tagawa
M
M
Tamura
M
M
Yuge
T
T
Fukuda
H
H
Nigi
H
H
D015502:Absorptiometry, Photon; D000818:Animals; D015519:Bone Density; D016723:Bone Remodeling / Q000187:drug effects; D002146:Bony Callus / Q000000981:diagnostic imaging / Q000187:drug effects*; D002452:Cell Count / Q000187:drug effects; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage / Q000494:pharmacology*; D017102:Fracture Healing / Q000187:drug effects*; D006801:Humans; D008297:Male; D010010:Osteoclasts / Q000187:drug effects; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D013977:Tibia / Q000000981:diagnostic imaging / Q000187:drug effects*; D013978:Tibial Fractures / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology
D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2